REG - Abingdon Health PLC - Launch of the Saliva Pregnancy self-test in Boots

Abingdon HealthAnnouncement

15/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240515:nRSO4334Oa&default-theme=true

RNS Number : 4334O  Abingdon Health PLC  15 May 2024

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY
VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Abingdon Health plc

("Abingdon Health" or "the Company")

 

Launch of the Saliva Pregnancy self-test in Boots

·    Boots will be the first retailer to sell the world's first saliva
pregnancy self-test under its own brand label

·    Tests will be available in Boots stores and online across the UK
provided by Abingdon Health, Salignostics and Crest Medical partnership

 

York, U.K. 15th May 2024: Abingdon Health plc (AIM: ABDX), a leading
international lateral flow Contract Development and Manufacturing Organisation
(CDMO), announces the launch of Boots own-brand, saliva pregnancy self-test
across the UK and online, in partnership with Salignostics and Crest Medical.

 

On 20(th) March 2024, Abingdon Health announced the launch of the first two
Boots branded self-tests - Iron and Vitamin D deficiency - in-store and online
at boots.com.

 

In another step toward strengthening this partnership with Boots, Abingdon
Health is now pleased to announce the launch of the first ever saliva
pregnancy test under the Boots own brand range. The test is being made
available in store and online at boots.com from Spring 2024 onwards. This
product launch allows more people to access a new way of testing for
pregnancy.

 

With the UK pregnancy self-test market expected to reach USD $56.7 million by
2033(1), this provides a strategic opportunity to launch, on an own-brand
basis, an innovative product in this growing market with the UK's leading
health and beauty retailer. With general consumer adoption of self-tests on
the rise (US $7.89 billion in 2023)(2), and a robust pipeline of products
within its CRO/CDMO offering, Abingdon Health is well positioned to continue
developing OEM retail relationships within the UK and Europe as a value-add,
innovative Private Label Supplier (PLS).

 

Chris Yates, CEO of Abingdon Health plc, commented: "We are delighted to
announce the launch of the Boots branded saliva pregnancy test in conjunction
with our partners Salignostics and Crest Medical. This launch showcases our
ability to deliver innovative and disruptive private label products through
our CDMO/CRO lateral flow full-service proposition with one of the most
trusted UK brands - Boots."

 

Guy Krief, Co-Founder and Deputy CEO of Salignostics Ltd, commented: "We are
delighted to partner on this exciting opportunity for our breakthrough
technology that has brought the first ever saliva pregnancy test to market.
Boots is the leading health and beauty retailer in the UK and offering our
saliva pregnancy test under their own brand label will drive consumer
education, confidence and adoption of the platform."

 

Matthew Courtney, CEO of Crest Medical Ltd, commented: "After the recent
release of Vitamin D and Iron deficiency testing under the Boots family of
products, the launch of the saliva pregnancy test is another terrific step
forwards in expanding our portfolio and deepening our partnership with
Abingdon Health."

 

Sources:

1.
https://www.futuremarketinsights.com/reports/at-home-pregnancy-testing-market
(https://www.futuremarketinsights.com/reports/at-home-pregnancy-testing-market)

2.     Self-testing Market Share, Growth, Demand, Forecast to 2033
(futuremarketinsights.com)
(https://www.futuremarketinsights.com/reports/self-testing-market)

 

Enquiries

 

 Abingdon Health plc                                     www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer
 Chris Hand, Non-Executive Chairman

 WH Ireland Limited (Sole Broker and Nominated Adviser)    Tel: +44 (0) 20 7220 1666
 Chris Fielding / Isaac Hooper (Corporate Finance)
 Fraser Marshall (Corporate Broking)

 

 

The person responsible for arranging the release of this announcement on
behalf of the Company is Chris Yates, Chief Executive Officer of the Company.

 

About Abingdon Health plc

 

Abingdon Health is a leading lateral flow contract development and
manufacturing organisation ("CDMO") offering its services to an international
customer base across industry sectors that include clinical, animal health,
plant health, and environmental testing. Abingdon Health has the internal
capabilities to take projects from initial concept through to routine and
large-scale manufacturing; from "idea to commercial success".

 

The Company's CDMO division offers product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format. Abingdon Health aims to support the increase in need for rapid
results across many industries and locations; and produces lateral flow tests
in areas such as infectious disease and clinical testing, including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making and targeted intervention; and can support
better outcomes.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com) e-commerce site offers consumers a range
of information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range is also sold through international distributors and through other
channels in the UK and Ireland, such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLGPUBWAUPCGQC